EP1933869
Notkun á lL-23 og lL-17 mótlyfjum til að meðhöndla augnbólgu sjálfsofnæmissjúkdóm.
:
EP Einkaleyfi fallið úr gildi:
30.8.2006:
14.10.2009:
06813945.0
:
19.1.2010:
15.2.2010
:
29.8.2026:
29.8.2013
:
USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
30.8.2006
14.10.2009
19.1.2010
15.2.2010
29.8.2013
:
Merck Sharp & Dohme Corp., (a New Jersey corporation):
126 East Lincoln Avenue, 07065, Rahway, US
:
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services:
National Institutes of Health Office of Technology Transfer Suite 325, 6011 Executive Boulevard, 20852-3804, Rockville, MD, US
:
CUA, Daniel, J.:
Boulder Creek, CA, US
:
KASTELEIN, Robert, A.:
Redwood City, CA, US
:
TSAI, Van, T.:
San Diego, CA, US
:
CASPI, Rachel:
Bethesda, MD, US
:
SILVER, Phyllis:
Silver Spring, MD, US
:
LUGER, Dror:
Rockville, MD, US
:
Árnason Faktor ehf.:
Guðríðarstíg 2-4, 113, Reykjavík,
:
713792 P:
1.9.2005:
US
:
837312 P:
11.8.2006:
US
:
WO2007027761:
30.8.2006
:
A61K 39/395, A61P 27/00
: 5
: 21.7.2010
: 31.8.2011
: Örn Þór, slf.
: 6
: 22.7.2011
: 29.8.2012
: Örn Þór, slf.
: 7
: 19.7.2012
: 29.8.2013
: Örn Þór, slf.